论文部分内容阅读
我国医疗制度改革的不断深入,给OTC药物管理制度的出台提供了现实可能性。国内外著名的制药厂商都看好中国这一潜在的大市场,都在积极进行各方面的准备工作,特别是一些敏感的三资企业,其OTC药品的产销工作已开始了实质性的启动。为了帮助读者更多地熟悉这方面的知识并了解这方面的信息,由《化学医药工业信息》编辑部、《上海医药》杂志社和《医药经济信息》编辑部联合主办的“OTC展望”栏目,今天与大家见面了。我们将组织有关专家发表自己的见解,为大家提供信息。欢迎读者提出意见和要求,帮助我们共同把这一栏目办好。 《化学医药工业信息》编辑部 《上海医药》杂志社 《医药经济信息》编辑部 1997年1月
The continuous deepening of the reform of China’s medical system has provided realistic possibilities for the introduction of OTC drug management systems. Well-known pharmaceutical manufacturers at home and abroad are optimistic about China’s potential large market and are actively carrying out preparations in all aspects. In particular, some sensitive foreign-funded enterprises have started substantive production of their OTC drugs. In order to help readers become more familiar with this knowledge and to understand this information, the “OTC Outlook” section co-sponsored by the “Chemical Industry Information” editorial department, “Shanghai Pharmaceutical” magazine and “Medicine Economic Information” editorial department Meet with you today. We will organize relevant experts to express their opinions and provide information for everyone. Readers are welcome to submit their opinions and requests and help us to manage this section. Editorial Department of “Chemical and Pharmaceutical Industry Information” “Shanghai Medical” magazine Editorial Department of “Medicine Economic Information” January 1997